You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lactoferrin as an Adjuvant for Cellular Immunity

    SBC: Pharmareview Corporation            Topic: N/A

    The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only include AIM I and AIM II of the proposal. There will be no change in scope to the first two aims. All experiments proposed in AIMs I and II can be accelerated to meet the two year time commitment. Regarding ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. DAT Selective Inhibitor As Cocaine Medication

    SBC: Novascreen Biosciences Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine addiction and dependency have reached pandemic levels and have become a continuing national healthcare concern. At present, no effective and safe medication is available to treat cocaine dependency and to ameliorate the underlying chemical addiction. During previous SBIR Phase I and Phase II supported work, we discovered several promising novel chemical ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Integrated Top-Down/Bottom-Up Comprehensive Proteomics

    SBC: CALIBRANT BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I: The R43 phase of this project aims to develop and demonstrate a capillary gel electrophoresis (CGE) based multidimensional protein separation platform capable of providing significant analyte concentration and extremely high resolving power for handling complex protein mixtures prior to mass spectrometry detection. In comparison with conventional SDS- ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Instant Kit Synthesis of 62Cu Radiopharmaceuticals

    SBC: PROPORTIONAL TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Positron Emission Tomography (PET) is a rapidly emerging non-invasive imaging technique with the exceptional ability to provide quantitative functional information. Unfortunately, this modality is currently limited to a single approved radiopharmaceutical agent, 18F-FDG, which measures tumor metabolism. The potential of PET in oncology can be advanced substa ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Therapy for Wet Age-Related Macular Degeneration

    SBC: ADVANCED VISION THERAPIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The blindness associated with wet AMD is caused by neovascularization and treatments are aimed at inhibiting this progress. The Advanced Vision Therapies, Inc. (AVT) strategy is to combine its gene deliver ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Repair of Factor VIII by targeted RNA trans-splicing

    SBC: INTRONN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Successful gene therapy will revolutionize the treatment of the inherited bleeding disorders hemophilia A and B. Hemophilia A is caused by deficiency of coagulation factor VIII (FVIII) and is a prime disorder for genetic correction. The disease constitutes 80% of all hemophilia patients and is the focus of this proposal. The requirements for successful FVIII ge ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Small Molecule Therapeutics to Treat Obesity

    SBC: FASGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): During the period of support provided by Phase I of SBIR-AT-NIDDK, 50 compounds were evaluated as a basis for drug development. The most promising of these compounds have been evaluated in a series of carefully integrated in-vitro experiments using informative cell lines and in-vivo studies in lean and diet induced- obese (DIO) mice, with special emphasis plac ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Interactive Image Guided Closed Loop Thermal Therapy

    SBC: Biotex, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II Competing Continuation research project is to complete the Phase I clinical trial of a new magnetic resonance imaging guided minimally invasive treatment for focal brain tumors. Over the past four years, BioTex has developed the Visualase(r) thermal therapy system for treatment of localized cancers by using temperature-sensitive mag ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Attenuated Sporozoite Malaria Vaccine

    SBC: SANARIA INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The recent call for elimination of malaria caused by Plasmodium falciparum and eventual eradication of all malaria has focused attention on this disease, which is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for eliminating P. falciparum, the causative agent of 99% of all malaria deaths, would be a highly effective ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a transgenic rat to study brain aging

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neuro-inflammation is thought to be an important factor in age-dependent loss of neuron associated with Alzheimer's disease. We seek STTR funding to develop a unique transgenic rat that serves as a model for chronic neuro-inflammation and age-dependent loss of neurons. Presently, no other animal model offers specific patterns of neuro-inflammation, presence of ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government